Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224-6823, USA.
Psychopharmacology (Berl). 2011 Dec;218(4):649-65. doi: 10.1007/s00213-011-2358-5. Epub 2011 Jun 15.
This dose-effect study extends previous observations showing that psilocybin can occasion mystical-type experiences having persisting positive effects on attitudes, mood, and behavior.
This double-blind study evaluated psilocybin (0, 5, 10, 20, 30 mg/70 kg, p.o.) administered under supportive conditions.
Participants were 18 adults (17 hallucinogen-naïve). Five 8-h sessions were conducted individually for each participant at 1-month intervals. Participants were randomized to receive the four active doses in either ascending or descending order (nine participants each). Placebo was scheduled quasi-randomly. During sessions, volunteers used eyeshades and were instructed to direct their attention inward. Volunteers completed questionnaires assessing effects immediately after and 1 month after each session, and at 14 months follow-up.
Psilocybin produced acute perceptual and subjective effects including, at 20 and/or 30 mg/70 kg, extreme anxiety/fear (39% of volunteers) and/or mystical-type experience (72% of volunteers). One month after sessions at the two highest doses, volunteers rated the psilocybin experience as having substantial personal and spiritual significance, and attributed to the experience sustained positive changes in attitudes, mood, and behavior, with the ascending dose sequence showing greater positive effects. At 14 months, ratings were undiminished and were consistent with changes rated by community observers. Both the acute and persisting effects of psilocybin were generally a monotonically increasing function of dose, with the lowest dose showing significant effects.
Under supportive conditions, 20 and 30 mg/70 kg psilocybin occasioned mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. Implications for therapeutic trials are discussed.
该剂量效应研究扩展了先前的观察结果,表明裸盖菇素可以引起迷幻型体验,对态度、情绪和行为产生持久的积极影响。
本双盲研究评估了在支持性条件下给予裸盖菇素(0、5、10、20、30mg/70kg,口服)的效果。
参与者为 18 名成年人(17 名未使用过致幻剂)。每位参与者在 1 个月的间隔内单独进行 5 次 8 小时的治疗。参与者被随机分配接受四种活性剂量,以升序或降序(每组 9 名)给药。安慰剂以准随机方式安排。在治疗期间,志愿者使用眼罩,并被指示将注意力向内引导。志愿者在每次治疗结束后立即以及 1 个月和 14 个月时完成评估治疗效果的问卷。
裸盖菇素产生了急性的知觉和主观效应,包括在 20 和/或 30mg/70kg 时,产生极度的焦虑/恐惧(39%的志愿者)和/或迷幻型体验(72%的志愿者)。在两个最高剂量的治疗结束后 1 个月,志愿者将裸盖菇素体验评为具有重要的个人和精神意义,并归因于体验带来了态度、情绪和行为的持续积极变化,升序剂量组显示出更大的积极效果。在 14 个月时,评分没有降低,与社区观察员评定的变化一致。裸盖菇素的急性和持续效应通常是剂量的单调递增函数,最低剂量显示出显著的效果。
在支持性条件下,20 和 30mg/70kg 的裸盖菇素引起迷幻型体验,对态度、情绪和行为产生持久的积极影响。讨论了对治疗试验的影响。